US/UK/Canada

Share

Links

Quotes

Genetic Analysis GA-map® enables cost-efficient and reliable mapping and profiling of gut microbiota via In Vitro Diagnostics (IVD) testing. Genetic Analysis is currently the only company globally that offers a patented and CE-marked standardized testing platform for microbiome analysis, the GA-map® Dysbiosis Test. GA has initiated an ambitious growth plan to rapidly grow the business over the next few years in the EU and US. We have proven our existing business model to molecular labs, and the Company is now ready, with the CE-marked GA-map®, to be commercialized in the current market for microbiota testing as well as to enter the market for companion diagnostics, where the test will be performed in combination with microbiota altering drugs. The growth plan will expand the commercialization through carefully selected distributors for vast expansion and strategic direct sales of the current product portfolio within Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD). Based on the competitive advantages that a standardized diagnostic platform will have in the microbiota field, compared to the current research-based tools, and the huge number of potential patients, we assess that the market for GA’s technology is significant.
Ronny Hermansen, CEO
GA accomplished essential milestones during the period by being granted patents in US, Japan, India and the EU. In June, we successfully completed the next generation of the GA-map® Dysbiosis Test with a CE mark. The next generation includes a built-in bacteria functionality reporting algorithm that will further reduce run-time for the lab. We expanded our distribution network with Eagle Bioscience in the US and reached a significant agreement with a lab chain in Germany to sell the GA-map® platform installation package. Finally – GA, together with the Norwegian University of Life Sciences, is developing the world’s first complete database of reference genomes, HumGut, a collection of about 30,000 genomes, covering the broad diversity of bacterial genomes found in the human gut. Mapping and unlocking the genes present in a healthy gut is instrumental for developing new diagnostics and better treatment regimes. We will actively use this powerful search engine and database to identify novel gut signatures which we can plug onto our GA map® technology platform to develop new innovative diagnostic markers within the microbiome field.
Ronny Hermansen, CEO
Pick a time period -
Tags ( Active)

Genetic Analysis AS and Thalys Medical Technology Group are pleased to announce the launch of a microbiome test to the Chinese Consumer Health market

OSLO, NORWAY/SHANGHAI, CHINA – 22. April 2025: Microbiome DX company Genetic Analysis AS (“GA”) and Thalys Medical Technology Group Corporation (“Thalys”) announces the launch of a microbiome test for the Consumer Health (D2C) market in China. The test is based on GA’s clinically validated microbiome test, the GA-map® Dysbiosis Test, but specifically adapted to suit the Chinese market. This strategic cooperation represents the launch of GA’s commercial presence in the fast-growing market Chinese market via its partner Thalys and their new Independent Clinical Lab (ICL) in Shanghai.The

Genetic Analysis AS publishes year-end report 2024

OSLO, NORWAY – 26 February 2025: Genetic Analysis AS (the "Company", Ticker: GEAN) hereby publishes the year-end report for the period 1 January - December 31, 2024. The year-end report is available as an attached file to this release and on the Company's website. Below is a summary of the report.Ronny Hermansen, CEO of Genetic Analysis, comments:“I am pleased to announce that GA achieved an all-time high in sales during Q4, as well as achieving a positive EBITDA for the first time in the company’s history. The signing of the commercial agreement with Ferring Pharmaceuticals December 2024

GENETIC ANALYSIS AND FERRING PHARMACEUTICALS ANNOUNCE A COLLABORATION TO DEVELOP A NEW MICROBIOME RAPID DIAGNOSTIC TEST

· Collaboration announced to develop and launch a new rapid microbiome-based PCR test, aiming to provide increased standardisation in a quickly evolving field of microbiome life science · Technology will allow researchers and clinicians to deploy Ferring’s Microbiome Health Index™ biomarker in a clinical setting, establish results in hours rather than weeks, and at much reduced costs · The rapid diagnostic test will utilize Genetic Analysis’ GA-map[®] platform's specialized multiplex algorithm, swiftly translating data into instant results and eliminating the necessity for additional

Genetic Analysis AS: Mandatory notification of trade – Primary Insiders

OSLO, NORWAY – 25 November 2024: Genetic Analysis AS (“GA” or “the Company”) announces that members of the management has bought GEAN-shares.Ronny Hermansen, CEO of Genetic Analysis AS, has through the fully owned company InVitroDia AS on Friday 22.11.2024 bought 73.400 GEAN shares at an average price of 0,42 NOK per share. The shares were acquired on the Spotlight Stock Market. Following the transaction, Ronny Hermansen including controlled company owns 1.113.600 shares and 716.668 options. Lars Tiller, Head of Operations of Genetic Analysis AS, has on Friday 22.11.2024 bought 30.000

Genetic Analysis AS: Interim report January – September 2024

OSLO, NORWAY – 15 November 2024: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for the third quarter and the first nine months of 2024. The interim report is available as an attached file to this release and on the Company's website. Below is a summary of the report.Ronny Hermansen, CEO of Genetic Analysis, comments:“I am pleased to announce that, although sales are usually slower during the summer, GA has been very productive in several areas to improve our product offering and complete important cost efficiency implementations. Our

Genetic Analysis AS: Publication of Half-year report 2024

OSLO, NORWAY – 30 August 2024: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for H1, and april - June 2024. The Half-year report is available as an attached file to this release and on the Company's website. Below is a summary of the report.Ronny Hermansen, CEO of Genetic Analysis, comments:“I am happy to see that GA continues to attract new Lab customers to use the GA-map® diagnostic system and that we are increasing our lead pipeline. Thus, our core business consisting of reagent kit sales increased 135 percent in Q2 compared to Q2

Genetic Analysis directed issue to major shareholders has now been registered with the Norwegian Register of Business Enterprises

Genetic Analysis AS' (“GA” or the “Company”) directed issue to current major shareholders and certain members of the board of directors and management has now been registered with the Norwegian Register of Business Enterprises (No. Foretaksregisteret).On July 1 and July 17, 2024, GA carried out the directed issue that provided the Company with NOK 5.42 million by issuance of 7,225,916 new shares, before issue costs. The direct Issue has now been registered with the Norwegian Register of Business Enterprises. After this, the Company's new registered share capital is NOK 29,629,962.60

Interim report January – September 2022

Oslo, Norway, November 1, 2022 – Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for the period January 1 – September 30, 2022. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.Genetic Analysis CEO Ronny Hermansen comments:“An important milestone ahead is the completion of our research use only (RuO) tool of the IBD prognostic marker, and we are thrilled to say that the project is well underway with good potential for completion of and RuO product by the end of the year. We

CORRECTION: Interim report January – June 2022

Correction: Correction of the previously disclosed press release since the headline stated January – March. The correct timeline for the interim report is January – June. Otherwise, there are no changes from the previously published press release. Oslo, Norway, August 18, 2022 – Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for the period January 1 – June 30, 2022. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.Genetic Analysis CEO Ronny Hermansen comments:“As the first

Interim report January – March 2022

Oslo, Norway, August 18, 2022 – Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for the period January 1 – June 30, 2022. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.Genetic Analysis CEO Ronny Hermansen comments:“As the first six months of 2022 have passed, I am proud to say that we keep on delivering on our objectives set out in the IPO. In the past quarter, we continued our preparation to expand globally to major markets and entered a strategic collaboration agreement

Interim report January – March 2022

Oslo, Norway, May 13, 2022 – Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for the period January 1 – March 31, 2022. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.Genetic Analysis CEO Ronny Hermansen comments:“As we look back on the first quarter of 2022, I am proud of all the milestones we’ve achieved in these few months. I often say that we are focused on building momentum supporting our vision to become a global leading diagnostic company within the microbiome field

Genetic Analysis strengthens its management team by hiring a Head of Operations

OSLO, NORWAY – 4 March 2022: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces today that the Company has strengthened its management team by hiring Mr. Lars Tiller as Head of Operations. Lars Tiller will be responsible for manufacturing and logistics activities in GA.As a result of the increased market demand for the GA-map diagnostic kits, GA has now strengthened its organisation with expertise and know-how from scale-up in the fast-growing diagnostic industry. As Head of Operations, Mr. Lars Tiller will be responsible for manufacturing and logistics and will

Year-End Report October – December 2021

(Oslo, 18 February 2022) Genetic Analysis AS (“GA” or “the Company”) hereby publishes the year-end report for the period 1 October – December 31, 2021. The year-end report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.Genetic Analysis CEO Ronny Hermansen comments:“The year of 2021 has passed, and we can look back on an eventful year filled with milestones like an oversubscribed IPO, successful listing at Spotlight Stock Market, the signing of IMD as a new high-volume lab in Europe, and the receival of a research grant of

IMD - Institut für Medizinische Diagnostik launches the GA-map® Microbiome Test in Germany

OSLO, NORWAY/BERLIN, GERMANY – 15 February 2022: Microbiome DX company Genetic Analysis AS (“GA”) and Institut für Medizinische Diagnostik (“IMD”), a part of the Medicover Group, announces today that IMD has launched the GA-map® Dysbiosis Test in Germany. IMD will activate its new Microbiome laboratory in February 2022 and add standardized microbiota testing to its existing test portfolio of products. This new Microbiota test offering will be marketed to customers in Germany and Europe.In 2021, Genetic Analysis launched the updated version of GA-map[®] Dysbiosis Test – the first CE-marked

The Microbiome Test from Genetic Analysis AS launched on a new technology platform, GA-map® Dysbiosis Test kit now commercially available on the Luminex MAGPIX® system

OSLO, NORWAY – 1. February 2022: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces that the Company has successfully completed the development and CE-marking of the GA-map® Dysbiosis Test for the Luminex MAGPIX® instrument system. Today the Company proudly launches GA-map® on a new platform; MAGPIX®.The MAGPIX® instrument is the most affordable instrument of the Luminex’s xMAP® instruments and it enables up to 50 plex using MagPlex® Microspheres. The MAGPIX® system is already a widely used platform and a large number of laboratories have already installed this

Genetic Analysis AS (GA) reports first commercial sales of the enhanced GA-map® Dysbiosis Test version 2

OSLO, NORWAY – 27[th] January 2022: Today, GA achieved another important milestone; first commercial sales of the new and enhanced version of the GA-map® Dysbiosis Test to the US market. This enhanced version has built in several important technical upgrades which significantly improves the user friendliness and sample throughput for the Lab customer.The new version of GA-map® Dysbiosis Test will enable the molecular labs to run the analysis faster, meaning decreased lead time and increased throughput for the Lab. Furthermore, the new version will lower the run-cost for the lab due to the

Genetic Analysis AS (GEAN): Mandatory notification of trade – Primary Insiders

OSLO, NORWAY - 13 January 2022: Genetic Analysis AS (“GA” or “the Company”) announce that members of the management have bought GEAN-shares.Ronny Hermansen, CEO in Genetic Analysis AS, has through the fully owned company InVitroDia AS today bought 14,488 GEAN-shares at an average price of 6,90 NOK per share. The shares were acquired on the Spotlight Stock Market. Following the transaction, Ronny Hermansen including controlled company owns 169.040 shares and 49,998 subscription rights. Eilert Aamodt, CFO in Genetic Analysis AS, has through the fully owned company E. B. Aamodt AS today

Genetic Analysis AS and Thalys Medical Technology Group enter Microbiome Laboratory Developed Test (LDT) agreement for the Chinese market

OSLO, NORWAY/SHANGHAI, CHINA – 13. January 2022: Microbiome DX company Genetic Analysis AS (“GA”) and Thalys Medical Technology Group Corporation (“Thalys”) announces today that the parties have entered a Laboratory Developed Test (LDT) agreement to evaluate and develop innovative diagnostic solutions for the rapidly growing human microbiota market in China. Thalys will use its Shanghai-based Medical Lab group to further develop and distribute tests based on Genetic Analysis’s GA-map® technology.Over the recent years, the Chinese human microbiome market has been witnessing considerable

Genetic Analysis summarizes a successful year

OSLO, NORWAY – 21 December 2021: 2021 has been an eventful year for Genetic Analysis (“GA” or “the Company”), in which the Company made strong progress in a market that is developing both fast and positively. The past year has been filled with important milestones like the signing of a new high-volume lab in Europe, oversubscribed IPO, successful listing at Spotlight Stock Market and the receival of a research grant of NOK 16 million to develop a new IBD test. GA has now entered an exciting new phase of its commercial journey as a listed company.CEO Ronny Hermansen comments“The global

Interim report January – September 2021

(Oslo, 9 November 2021) Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for the period January 1 – September 30, 2021. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.Genetic Analysis CEO Ronny Hermansen comments:“We see the microbiome as a gamechanger in health and medicine moving forward. The Company’s recent financial injection paired up with our pioneering technology puts GA in an excellent position to realize our goal of being at the forefront of microbiome diagnostics

Genetic Analysis awarded important US patent covering a companion diagnostic method for optimising IBS interventions

OSLO, NORWAY - 28 October 2021: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces the award of an important patent (US20200400666) by the United States Patent and Trademark Office (USPTO) entitled “A COMPANION DIAGNOSTIC METHOD FOR USE IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIETARY INTERVENTIONS OR FAECAL MICROBIOTA TRANSPLANT”. The invention covered provides a diagnostic method to be used to determine the likelihood that a patient with Irritable Bowel Syndrome (IBS) will respond to treatment with a low-FODMAP diet or Faecal Microbiota Transplant (FMT).

Genetic Analysis enters a Service Agreement with Eurofins ADME BIOANALYSES – The first CRO to offer the GA-map® Microbiome test

OSLO, NORWAY – 19 October 2021: Molecular diagnostics specialist, Genetic Analysis AS (GA) today announced a Service Agreement with Eurofins ADME BIOANALYSES, a Contract Research Organisation (CRO) providing diverse services to the pharmaceutical industry in the fields of pharmacokinetics, pharmacodynamics and drug metabolism.There is increasing demand for the inclusion of gut microbiome assessments in clinical trials and clinical trial research. Eurofins ADME BIOANALYSES’ launch of GA-map® Dysbiosis Test, a CE marked standardised gut microbiome test by Eurofins ADME BIOANALYSES will

Genetic Analysis receives important patent allowance in China

OSLO, NORWAY - 14 October 2021: Microbiome DX company Genetic Analysis AS (“GA” or “the Company”) announces that the Company has been awarded an important patent (CN107430644A) by the China National Intellectual Property Agency (CNIPA). The patent entitled “A METHOD FOR DETERMINING GASTROINTESTINAL TRACT DYSBIOSIS” covers the Company’s unique algorithm incorporated in the GA-map® technology for profiling gut microbiota. The positive decision from the Chinese patent authority means that the protection of the GA-map® technology has been substantially strengthened and will further support the

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe